Compounds > ly 293111
Page last updated: 2024-09-05

ly 293111 and Pancreatic Neoplasms

ly 293111 has been researched along with Pancreatic Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adrian, TE; Ding, XZ; Hennig, R; Pour, PM; Standop, J; Tong, WG; Witt, RC1
Adrian, TE; Bell, RH; Ding, XZ; Talamonti, MS1
Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E1
Adrian, TE; Bell, RH; Ding, XZ; Talamonti, MS; Tong, WG2

Reviews

1 review(s) available for ly 293111 and Pancreatic Neoplasms

ArticleYear
A novel anti-pancreatic cancer agent, LY293111.
    Anti-cancer drugs, 2005, Volume: 16, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Proliferation; Humans; Pancreatic Neoplasms; PPAR gamma; Receptors, Leukotriene B4

2005

Other Studies

4 other study(ies) available for ly 293111 and Pancreatic Neoplasms

ArticleYear
Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Animals; Apoptosis; Benzoates; Blotting, Western; Cell Division; Female; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Leukotriene B4; Mice; Mice, Inbred BALB C; Microscopy, Polarization; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Receptors, Leukotriene B4; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured

2002
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Time Factors

2005
LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways.
    Biochemical and biophysical research communications, 2005, Sep-30, Volume: 335, Issue:3

    Topics: Androstadienes; Arachidonate 5-Lipoxygenase; Benzoates; Butadienes; Cell Division; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Flavonoids; Humans; Leukotriene B4; Mitogen-Activated Protein Kinases; Nitriles; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Signal Transduction; Wortmannin

2005
Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells.
    Anti-cancer drugs, 2007, Volume: 18, Issue:5

    Topics: Apoptosis; bcl-2-Associated X Protein; Benzoates; Blotting, Western; Caspase 3; Caspase 7; Caspase 9; Cell Cycle; Cell Line, Tumor; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Enzyme Activation; Flow Cytometry; Genes, bcl-2; Humans; Leukotriene Antagonists; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Leukotriene B4; S Phase

2007